Nicotinamide Riboside Shows Promise for Rare Aging Disease Werner Syndrome
First clinical trial of NAD+ precursor in Werner syndrome patients shows improved arterial stiffness and reduced skin ulcers with no serious side effects.
Summary
Researchers conducted the first clinical trial of nicotinamide riboside (NR) in patients with Werner syndrome, a rare genetic aging disease. Nine patients took 1000mg NR daily for 26 weeks in a crossover trial. NR significantly improved arterial stiffness, reduced skin ulcer area, and showed trends toward preventing heel pad thinning. Blood analysis revealed decreased creatinine levels, suggesting potential kidney protection. No serious side effects occurred, making this the first promising treatment for this devastating condition that typically causes death by age 59.
Detailed Summary
Werner syndrome is a devastating genetic aging disease caused by mutations in the WRN gene, leading to premature development of age-related conditions and death around age 59. Previous research showed these patients have depleted NAD+ levels, a crucial cellular energy molecule, suggesting supplementation might help.
Researchers at Chiba University conducted the first clinical trial of nicotinamide riboside (NR), an NAD+ precursor, in Werner syndrome patients. This double-blind, randomized crossover study enrolled 9 patients (average age 47) who took either 1000mg NR or placebo daily for 26 weeks, then switched treatments for another 26 weeks.
The results were encouraging. NR significantly improved the cardio-ankle vascular index (CAVI), a measure of arterial stiffness that predicts cardiovascular disease risk. Patients also experienced reduced skin ulcer area and showed trends toward preventing heel pad thinning, a characteristic feature of the syndrome. Metabolomic analysis revealed significantly decreased blood creatinine levels, suggesting NR may protect kidney function.
Importantly, no serious adverse events occurred during NR treatment, establishing its safety profile in this vulnerable population. The study included comprehensive monitoring of NAD+ levels, blood parameters, sarcopenia measures, and cardiovascular indices.
These findings represent a potential breakthrough for Werner syndrome, which currently has no standard treatment beyond managing symptoms. The improvements in arterial stiffness and skin ulcers address two major complications that significantly impact patients' quality of life and survival. However, the small sample size and relatively short duration limit broader conclusions about long-term efficacy.
Key Findings
- Significant improvement in cardio-ankle vascular index (CAVI), indicating reduced arterial stiffness
- Decreased skin ulcer area in patients with chronic wounds
- Trend toward preventing heel pad thinning, a characteristic Werner syndrome feature
- Significantly decreased blood creatinine levels, suggesting potential kidney protection
- No serious adverse events reported during 26 weeks of 1000mg daily NR treatment
- Study included 9 patients with average age 47 years in crossover design
- 88.9% of patients had type 4 WRN gene mutations, the most common Japanese variant
Methodology
Double-blind, randomized crossover placebo-controlled trial with 9 Werner syndrome patients. Participants received 1000mg nicotinamide riboside or placebo daily for 26 weeks, then crossed over for another 26 weeks. Primary endpoint was safety; secondary endpoints included NAD+ levels, skin ulcers, cardiovascular measures, and metabolomic profiles. Statistical analysis used appropriate crossover methodology.
Study Limitations
Small sample size of only 9 patients limits statistical power and generalizability. Relatively short 26-week treatment periods may not capture long-term effects or safety concerns. The study was conducted in a Japanese population with predominantly type 4 WRN mutations, potentially limiting applicability to other genetic variants. Authors noted the need for larger, longer-duration studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.